{
  "resourceType": "MedicinalProductDefinition",
  "id": "equilidem-with-ing-and-auth",
  "text": {
    "status": "generated",
    "div": "\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: equilidem-with-ing-and-auth\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: Equilidem25\u003c/p\u003e\u003cp\u003e\u003cb\u003ecombinedPharmaceuticalDoseForm\u003c/b\u003e: \u003cspan\u003etablet\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eindication\u003c/b\u003e: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class \u0026gt;\u003d II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\u003c/p\u003e\u003cp\u003e\u003cb\u003elegalStatusOfSupply\u003c/b\u003e: \u003cspan\u003ePrescription only medicine\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eclassification\u003c/b\u003e: \u003cspan\u003eB01A\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eingredient\u003c/b\u003e: \u003c/p\u003e\u003cul\u003e\u003cli\u003e\u003ca\u003e \u003c/a\u003e\u003c/li\u003e\u003cli\u003e\u003ca\u003e \u003c/a\u003e\u003c/li\u003e\u003c/ul\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: EquilidoniumPhosphate\u003c/p\u003e\u003cp\u003e\u003cb\u003erole\u003c/b\u003e: \u003cspan\u003eactive\u003c/span\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003esubstance\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003ecode\u003c/b\u003e: \u003cspan\u003eEquilidonium Phosphate\u003c/span\u003e\u003c/p\u003e\u003ch3\u003eStrengths\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003ePresentation\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003e22 ml/1 tablet\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: CalciumCarbonate\u003c/p\u003e\u003cp\u003e\u003cb\u003erole\u003c/b\u003e: \u003cspan\u003eexcipient\u003c/span\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003esubstance\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003ecode\u003c/b\u003e: \u003cspan\u003eCalcium Carbonate\u003c/span\u003e\u003c/p\u003e\u003ch3\u003eStrengths\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003ePresentation\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003e3 ml/1 tablet\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003ch3\u003eNames\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eProductName\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eEquilidem 2.5 mg film-coated tablets\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eCrossReferences\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eProduct\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eManufacturingBusinessOperations\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eManufacturer\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003e\u003cspan\u003eEquiliDrugCo Processing Inc.\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/div\u003e"
  },
  "contained": [
    {
      "resourceType": "Ingredient",
      "id": "EquilidoniumPhosphate",
      "role": {
        "coding": [
          {
            "system": "http://example.org.uk/fhir/ingredientType",
            "code": "active"
          }
        ]
      },
      "substance": {
        "codeCodeableConcept": {
          "coding": [
            {
              "system": "http://example.org.uk/fhir/substances",
              "code": "123456",
              "display": "Equilidonium Phosphate"
            }
          ]
        },
        "strength": [
          {
            "presentation": {
              "numerator": {
                "value": 22,
                "unit": "ml"
              },
              "denominator": {
                "value": 1,
                "unit": "tablet"
              }
            }
          }
        ]
      }
    },
    {
      "resourceType": "Ingredient",
      "id": "CalciumCarbonate",
      "role": {
        "coding": [
          {
            "system": "http://example.org.uk/fhir/ingredientType",
            "code": "excipient"
          }
        ]
      },
      "substance": {
        "codeCodeableConcept": {
          "coding": [
            {
              "system": "http://example.org.uk/fhir/substances",
              "code": "456789",
              "display": "Calcium Carbonate"
            }
          ]
        },
        "strength": [
          {
            "presentation": {
              "numerator": {
                "value": 3,
                "unit": "ml"
              },
              "denominator": {
                "value": 1,
                "unit": "tablet"
              }
            }
          }
        ]
      }
    }
  ],
  "identifier": [
    {
      "system": "http://example.org.uk/fhir/product",
      "value": "Equilidem25"
    }
  ],
  "combinedPharmaceuticalDoseForm": {
    "coding": [
      {
        "system": "http://example.org.uk/fhir/dosefom",
        "code": "tablet"
      }
    ]
  },
  "indication": "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class \u003e\u003d II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",
  "legalStatusOfSupply": {
    "coding": [
      {
        "system": "http://example.org.uk/fhir/legalstatusofsupply",
        "code": "POM",
        "display": "Prescription only medicine"
      }
    ]
  },
  "classification": [
    {
      "coding": [
        {
          "system": "http://www.whocc.no/atc/example",
          "code": "B01A"
        }
      ]
    }
  ],
  "ingredient": [
    {
      "reference": "#EquilidoniumPhosphate"
    },
    {
      "reference": "#CalciumCarbonate"
    }
  ],
  "name": [
    {
      "productName": "Equilidem 2.5 mg film-coated tablets"
    }
  ],
  "crossReference": [
    {
      "product": {
        "reference": {
          "reference": "MedicinalProductDefinition/genericEquilidonium"
        }
      }
    }
  ],
  "manufacturingBusinessOperation": [
    {
      "manufacturer": [
        {
          "display": "EquiliDrugCo Processing Inc."
        }
      ]
    }
  ],
  "meta": {
    "tag": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-ActReason",
        "code": "HTEST",
        "display": "test health data"
      }
    ]
  }
}